Investment and Company Research
Opportunity Research
MICROCAP HOT TOPICS
 

 

April 1, 2015

Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech

It is no secret that the best performing sector for some time has been healthcare.  A recent flurry of M&A deals has proven that this trend is primed to continue. Moreover, given the premiums paid in these transactions, PharmaCyte Biotech, Inc. (OTCQB – PMCB – $0.1394 – Spec Buy) may be sitting in the catbird seat as an unusually attractive potential target.

Why?

Major pharmaceutical companies are in panic mode.  They are staring in the face of patent expirations on key products representing hundreds of millions or billions in revenue on one side, and competition for their big sellers from peers and upstarts in mid-late stage clinical trials on the other side.  To fend off these attacks, management teams have entered into a quasi-arms race in their quest to rapidly add companies via acquisition that complement their current therapeutic categories.  This environment has led to a 59% increase in healthcare M&A for the quarter to $89 billion, up from $56 billion in 1Q14.  As noted in a recent Marketwatch.com article (http://www.marketwatch.com/story/three-health-care-deals-today-are-paying-huge-premiums-2015-03-30), the premiums paid on recent acquisitions, including two of the three just announced this week, represent an average 30-day premium of 60%. Teva Pharmaceutical is buying Auspex Pharmaceutical for more than $3 billion, which represents a 50% premium to the previous day’s close for a non-revenue generating company with products in a series of clinical trials. 

Since the Company’s Cell-in-a-Box(R) live cell encapsulation technology has such broad potential applications, it could emerge as a universal therapy for the treatment of multiple forms of cancer and diabetes and compete with a number of existing, billion dollar products, potentially making PharmaCyte Biotech the prototypical acquisition target.  

Most early stage and mid-stage companies such as PharmaCyte Biotech are keenly aware of big pharma’s desire to acquire firms with unique technology that can potentially treat diseases representing billions in market opportunity, and are therefore wisely built for potential sale. As a result, early and mid-stage clinical trials are designed not just for maximum efficacy and safety but to attract the attention of the world’s biggest pharmaceutical players. With three separate clinical trials this year featuring its proprietary technology, PharmaCyte Biotech could be high on the industry’s radar screen once the trials are completed and the results are released.

For more information, refer to our previous sponsored PMCB Reports, Updates and Hot Topic Articles by visiting http://www.GoldmanResearch.com/

Senior Analyst: Robert Goldman

Rob Goldman founded Goldman Small Cap Research in 2009 and has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

Analyst Certification

I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

Disclaimer

This Microcap Hot Topics Article was prepared for informational purposes only.

Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select format reflects the Firm’s internally generated stock ideas along with economic and stock market outlooks. Opportunity Research reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored microcap research ideas that typically carry greater risks than those stocks covered in the Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research reports on profiled stocks in the Opportunity Research format typically have a higher risk profile, and may offer greater upside. In 2015, Goldman Small Cap Research has been compensated by a third party in the amount of $6500 for a research subscription service and a series of articles. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information published by the Company, or other firms. Goldman Small Cap Research relied solely upon information published by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.

A Goldman Small Cap Research report or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This publication does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com